摘要
目的：探讨哌罗匹隆与利培酮治疗首发精神分裂症患者的临床疗效和安全性。方法将70例首发精神分裂症患者随机分为两组，分别口服哌罗匹隆和利培酮治疗，观察8周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗8周末，哌罗匹隆组总有效率87．9％，利培酮组为85．3％，两组比较差异无显著性（χ^2＝0．10，P＞0．05）。哌罗匹隆组不良反应发生率为60．0％，利培酮组为62．9％，两组比较差异无显著性（χ^2＝0．06，P＞0．05），但哌罗匹隆组内分泌改变及体质量增加发生率显著低于利培酮组（χ^2＝5．08、5．08，P＜0．05）。结论哌罗匹隆与利培酮治疗首发精神分裂症疗效显著，安全性高，依从性好，但哌罗匹隆较少引起内分泌改变和体质量增加，尤其适用于女性首发精神分裂症患者。
Objective To explore the efficacy and safety of perospirone and risperidone in first-episode schizophrenia （FES） .Methods Seventy FES patients were randomly divided into two groups ,they took orally perospirone and risperidone respectively for 8 weeks .Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results At the end of the 8th week total effective rate was respectively 87 .9% in perospirone and 85 .3% in risperidone group ,which showed no significant difference （χ^2 =0 .10 ,P〉0 .05） .Incidences of adverse reactions were 60 .0% in perospirone and 62 .9% in risperidone group ,which showed no significant difference （χ^2 =0 .06 ,P〉0 .05） ,but those of endocrine alteration and weight gain were significantly lower in perospirone than risperidone group （χ ^2 =5 .08 ,5 .08 ;P〈0 .05） .Conclusion Perospirone has an evident effect equivalent to risperidone ,higher safety and better compliance in FES ,but the former causes endocrine alteration and weight gain less and is more suitable for female FES patients .
出处
《临床心身疾病杂志》
CAS
2014年第4期30-31,39,共3页
Journal of Clinical Psychosomatic Diseases
